CME credits: 0.75

Valid until: 15-04-2022

Claim your CME credit at https://reachmd.com/programs/cme/fight-covid-19-neutralizing-mabs/12403/

As of February 2022, information originally presented in the original broadcast has been updated. Due to the rise of the omicron variant, two combination therapies no longer carry EUA: bamlanivimab+eteseviman and casirivimab+imdevimab.

Neutralizing monoclonal antibodies (mAbs) first received emergency use authorization (EUA) in November 2020 for treating at-risk patients with COVID-19, and the field has continued to evolve since that time. This presentation provides an update in the latest evidence showing reduced severe illness and hospitalization in patients treated with neutralizing mAbs. This presentation will also answer your questions from multidisciplinary expert perspectives in identifying EUA-appropriate patients and administering outpatient infusion therapies: Robert Gottlieb, MD, PhD; Marilyn Bulloch, PharmD, BCPS, FCCM; and Tesha Seabra, MSN, RN.